Amicus Therapeutics
FOLD
FOLD was delisted on the 24th of April, 2026.
203 hedge funds and large institutions have $2.62B invested in Amicus Therapeutics in 2020 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 66 increasing their positions, 71 reducing their positions, and 49 closing their positions.
208% more call options, than puts
Call options by funds: $13.5M | Put options by funds: $4.36M
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
2.28% more ownership
Funds ownership: 107.98% → 110.26% (+2.3%)
2% less capital invested
Capital invested by funds: $2.68B → $2.62B (-$59.4M)
7% less repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 71
9% less funds holding
Funds holding: 224 → 203 (-21)
39% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 49
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$59.3M |
| 2 |
ClearBridge Investments
New York
|
+$35.7M |
| 3 |
DM
Deerfield Management
New York
|
+$30.9M |
| 4 |
JP Morgan Chase
New York
|
+$26.3M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$23.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$49.7M |
| 2 |
Jennison Associates
New York
|
-$20M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$17.1M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$16M |
| 5 |
CCM
Cadian Capital Management
New York
|
-$13.5M |
FOLD Hedge Fund Activity: Q1 2020 in Review
203 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q1 2020, worth a combined $2.62B — down 2.2% from $2.68B a quarter earlier.
Sellers outnumbered buyers: 49 funds closed out of FOLD and 30 opened new positions — a net loss of 19 holders — while 71 trimmed existing stakes and 66 added.
The largest buyer was Fidelity Investments, adding an estimated $59.3M. The largest seller was Invesco, cutting an estimated $49.7M.
- 203 institutional investors held Amicus Therapeutics (FOLD) as of Q1 2020, down from 224 in Q4 2019.
- Funds reported $2.62B of Amicus Therapeutics stock for Q1 2020, down 2.2% quarter-over-quarter.
- 30 funds opened new Amicus Therapeutics positions in Q1 2020 and 49 closed out, a net change of -19 holders.
- The largest Amicus Therapeutics buyer in Q1 2020 was Fidelity Investments, an estimated $59.3M added.
- The largest Amicus Therapeutics seller in Q1 2020 was Invesco, an estimated $49.7M sold.
Based on aggregated 13F filings for Q1 2020.